Pharmacological inhibitors

Finley, P.R., Selective serotonin re-uptake inhibitors pharmacologic profiles and potential therapeutic distinctions, Ann. Pharmacother., 28(12), 1359-1369, 1994. 

Suzdak, P. D., Erederiksen, K., Andersen, K. E., Sorensen, P. O., Knutsen, L. J. S., Nielsen, E. B. NNC-711, a novel potent and selective y-aminobutyric acid uptake inhibitor pharmacological characterization. 

Hiemke C. and S. Harther (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology and Therapeutics 85 11-28. 

J., Wong, E., Xu, L.-J., Young, R. N., Zamboni, R., Riendeau, D. Rofecoxib [Vioxx, MK-0966 4-(4 -methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone] a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J. Pharmacol. Exp. Ther. 1999, 290, 551-560,... 

Spector R, Vesell ES. The power of pharmacological sciences the example of proton pump inhibitors. Pharmacology 2006, 76, 148-155 discussion 156. 

White CM, Thrombin-directed inhibitors pharmacology and clinical use, Am Heart J 2005 I49 S54-S60. 

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res 67 209-217... 

Herling AW, Bickel M, Lang HJ, Weidmann K, Rosner M, Metzger H, Rippel R, Nimmesgem H Scheunemann KH (1988) A substituted thienol[3.4-d]imidazole versus substituted benzimida-zoles as H+,K+-ATPase inhibitors. Pharmacology 36 289-297... 

Israel DM, Hassall E. Omerprazole and other proton pump inhibitors pharmacology, efficacy, and safety, with special reference to use in children. J Pediatr Gastroenterol Nutr 1998 27(5) 568-79. 

Kolhnaimsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan—a novel topoisomerase I inhibitor pharmacology and cUnical experience. Oncology 1999 56(1) 1-12. 

Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998 56 307-335. 

Kokka, N., Clemons, G.K., and Lomax, P., Relationship between the temperature and endocrine changes induced by cholinesterase inhibitors. Pharmacology, 34, 74, 1987. Yang, Q.J. and Wamick, J.E., Effect of sarin and soman on spinal reflexes in the cat. NeuroscL Abstr., 9, 230A, 1983. 

Jansen PM, van den Meiracker AH, Jan Danser AH (2009) Aldosterone synthase inhibitors pharmacological and clinical aspects. Curr Opin Invest Drugs 10 319-326... 

Virag, L., and Szabo, C., 2002. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacological Reviews. 54 375-429. 

Traxler, P. and Furet, P. (1999) Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacology and Therapeutics, 82, 195-206. 

Colovic, M.B., Krstic, D.Z., Lazarevic-Pasti, T.D., et al., 2013. Acetylcholinesterase inhibitors pharmacology and toxicology. Curr. Neuropharmacol. 11,315-335. 

The pharmacotherapy of allergy and asthma has traditionally focused on the effecter molecules of the allergic cascade. They identified [91] and extended a novel family of 2-(substituted phenyl)benzimidazole inhibitors. Pharmacological activity depends on an intact phenylbenzimidazole-bis-amide backbone, and is optimized by the presence of lipophilic terminal groups 144. The broad profile of these compounds thus underscores their potential for treating the multifarious pathology of asthma. 

---